Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high...

Primary tabs

field_vote: 
Average: 8 (1 vote)
Publication type: 
Number of included patients: 
References: 
Therapeutic intervention: 
Therapeutic Substance(s): 

J Exp Clin Cancer Res. 2007 Dec;26(4):475-82.
Metronomic
chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative
adjuvant therapy in colorectal cancer at high risk to recurrence.
Ogata Y, Mori S, Ishibashi N, Akagi Y, Ushijima M, Murakami H, Fukushima T, Shirouzu K.Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.

study was designed to evaluate the antitumor efficacy and feasibility
of postoperative adjuvant metronomic chemotherapy using weekly
low-dosage CPT-11 and UFT in colorectal cancer at high risk to
recurrence.
 
A total of 49 patients (24 stage IIIb and 25 distant
metastasis) who underwent a R0 operation were enrolled in this
prospective study. Forty mg/m2 of CPT-11 were administered on day 1,
day 8, and on day 15 in 28-day cycles. A dosage of 335 mg/m2/day of UFT
was given perorally on daily schedule. Cycles were repeated for 6
months, and were followed by UFT alone for further 6 months.
 
One or
more adverse effects were seen in 43 of the 49 patients. However, most
of these effects were mild at grade 1 or 2: with only nausea in 3
patients, vomiting in 2, leucopenia in 2 and neutropenia in 2 at grade
3. The overall survival rates were favorable both in the stage IIIb
group (5-year: 73%) and in the distant metastases group (5-year: 62%).
Postoperative adjuvant metronomic chemotherapy using weekly low-dosage
CPT-11 and UFT might be safe and feasible and prolong survival time in
colorectal cancer at high risk to recurrence.